Earnings release · ABT
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Abbott Laboratories · Filed · SEC Form 8-K, Item 2.02
Revenue
—
+14.5% vs a year ago
EPS
$0.53
not detected
Guidance
maintainedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete.
Please read the original before relying on any figure. Not investment advice.
Why it matters
Revenue rose 14.5% year on year, and EPS was $0.53. The company kept its outlook unchanged, so the reported quarter did not change management's expectations for the periods ahead.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
What the company states
Revenue
n/a +14.5% vs a year ago
…Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis.…
EPS
$0.53
…Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.…
Guidance
Guidance maintained
…Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance –Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent –Third-quarter GAAP diluted EPS of $…
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.